Kriegsmann, Katharina
Baertsch, Marc-Andrea
Awwad, Mohamed H. S.
Merz, Maximilian
Hose, Dirk
Seckinger, Anja
Jauch, Anna
Becker, Natalia
Benner, Axel
Raab, Marc S.
Hillengass, Jens
Bertsch, Uta
Dürig, Jan
Salwender, Hans Jürgen
Hänel, Mathias
Fenk, Roland
Munder, Markus
Weisel, Katja
Müller-Tidow, Carsten
Goldschmidt, Hartmut
Hundemer, Michael
Article History
Received: 31 July 2018
Revised: 4 October 2018
Accepted: 27 December 2018
First Online: 29 January 2019
Conflict of interest
: K.K.: Research Support BMS, Celgene, Sanofi, Morphosys. M.-A.B.: Travel grants: Amgen, Novartis, Bristol-Myers Squibb, Janssen, Sanofi; Honoraria: Novartis, Takeda. M.Merz: Travel grants: Celgene, Takeda, AMGEN, Janssen; Advisory Board: AMGEN; Research grant: Takeda. M.R.: research funding from Novartis, Amgen, Morphosys. J.H.: honoraria from Amgen, BMS, Celgene, Janssen; research support from Sanofi; advisory boards: Amgen, Celegene, Janssen, Novartis. K.W.: advisory board and honoraria: AMGEN, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Takeda, Onyx; research funding: Janssen, Celgene. H.J.S.: honoraria and travel support: Janssen Cilag, Celgene, Bristol Meyer Squibb. M.H.: honoraria Roche, Novartis. R.F.: Honoraria and travel grants: Celgene, Janssen, BMS; research funding: Celgene. M.Munder: Consultancy: Janssen Cilag, BMS, Takeda, Amgen, Celgene. J.D.: advisory Board: Bristol-Myers Squibb, Celgene, Janssen; speakers bureau: Celgene, Janssen; research funding: Celgene. H.G.: Research support: Celgene, Janssen, Chugai, Novartis, BMS; Advisory boards: Janssen, Celgene, Novartis, Amgen, Takeda, BMS; Honoraria: Celgene, Janssen, Novartis, Chugai, BMS. M.H.: Research support: BMS, Celgene, Sanofi, Morphosys. The other authors declare that they have no conflict of interest.